目的:评估早期生长反应3(EGR3)在正常皮肤和不同类型皮肤肿瘤中的表达:皮肤鳞状细胞癌(cSCC),基底细胞癌(BCC),黑色素瘤(MM),和含有皮脂腺癌(SC)的皮肤附件肿瘤,毛上皮瘤(TE)和透明细胞腺瘤(CCH)。
背景:EGR3在多个器官中表达,包括皮肤,在细胞分化和肿瘤生长中起着重要作用。先前的研究表明,EGR3抑制肿瘤生长,并在各种恶性肿瘤中下调。然而,其在正常皮肤中的分布及其在皮肤肿瘤中的表达尚未被研究。
方法:正常病例样本(n=4),cSCC(n=12),BCC(n=12),MM(n=12),SC(n=4),TE(n=4),和CCH(n=4)来自2018年至2023年在我们部门接受治疗的患者.免疫组织化学检测EGR3的表达。用染色模式和组织化学评分的描述对结果进行分析。
结果:免疫组织化学染色显示,EGR3在正常皮肤的颗粒层和棘层上部独特表达,以及皮脂腺和毛囊,但不是在汗腺里.在皮肤癌中,密件抄送,SC,TE显示EGR3染色阳性,而cSCC,MM,CCH是阴性的。
结论:EGR3在正常皮肤和皮肤肿瘤中具有特定的表达模式,这对皮肤肿瘤的鉴别诊断很重要,特别是对于cSCC和皮脂腺癌。
OBJECTIVE: To assess the expression of early growth response 3 (EGR3) in normal skin and different types of skin tumors: cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), melanoma (MM), and cutaneous adnexal tumors containing sebaceous carcinoma (SC), trichoepithelioma (TE) and clear cell hidradenoma (CCH).
BACKGROUND: EGR3, expressed in multiple organs, including skin, plays an important role in cell differentiation and tumor growth. Previous studies have shown that EGR3 suppresses tumor growth and is downregulated in various malignancies. However, its distribution in normal skin and its expression especially in skin tumors have not been studied.
METHODS: Samples of normal cases (n = 4), cSCC (n = 12), BCC (n = 12), MM (n = 12), SC (n = 4), TE (n = 4), and CCH (n = 4) were collected from patients treated in our department between 2018 and 2023. Immunohistochemistry was used to investigate the expression of EGR3. The results were analyzed with the description of the staining pattern and the histochemical score.
RESULTS: Immunohistochemical staining showed that EGR3 was uniquely expressed in normal skin in the granular layer and upper part of the stratum spinosum, as well as in sebaceous glands and hair follicles, but not in sweat glands. In skin cancers, BCC, SC, and TE showed positive EGR3 staining, whereas cSCC, MM, and CCH were negative.
CONCLUSIONS: EGR3 has a specific expression pattern in normal skin and in skin tumors, which is important for the differential diagnosis of skin tumors, in particular for cSCC and sebaceous gland carcinoma.